Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 20/20 | 0.74 |
| ▸ | CHEK2 | O96017 | 5/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.65 |
| ▸ | CDK1 | P06493 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12983870 | 0.85 | CHEK1 (1.00) | CHEK1CHEK2KCNH2CDK1 | |
| SCHEMBL1396935 | 0.85 | CHEK1 (1.00) | CHEK1CHEK2KCNH2CDK1 | |
| SCHEMBL12985426 | 0.79 | CHEK1 (0.82) | CHEK1CHEK2KCNH2CDK1 | |
| SCHEMBL12984696 | 0.79 | CHEK1 (0.82) | CHEK1CHEK2KCNH2CDK1 | |
| SCHEMBL20516616 | 0.79 | CHEK1 (0.82) | CHEK1CHEK2KCNH2CDK1 | |
| SCHEMBL13029116 | 0.79 | CHEK1 (0.82) | CHEK1CHEK2KCNH2CDK1 | |
| SCHEMBL30637885 | 0.79 | CHEK1 (0.82) | CHEK1CHEK2KCNH2CDK1 | |
| SCHEMBL20516611 | 0.79 | CHEK1 (0.82) | CHEK1CHEK2KCNH2CDK1 | |
| SCHEMBL13028631 | 0.79 | CHEK1 (0.80) | CHEK1CHEK2KCNH2CDK1 | |
| SCHEMBL1396946 | 0.79 | CHEK1 (1.00) | CHEK1CHEK2KCNH2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776417-B1 | 5-(PYRIDIN-2-YL-AMINO)-PYRAZINE-2-CARBONITRILE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECH LTD (GB) | 2018-10-31 | — | — | EP | disclosed |
| US-9765059-B2 | 5-(Pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-09-19 | — | — | US | disclosed |
| US-9765059-B2 | 5-(Pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-09-19 | — | — | US | disclosed |
| US-20160304493-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-10-20 | — | — | US | disclosed |
| US-20160304493-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-10-20 | — | — | US | disclosed |
| US-9403797-B2 | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-02 | — | — | US | disclosed |
| US-9403797-B2 | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-02 | — | — | US | disclosed |
| US-20150225372-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-13 | — | — | US | disclosed |
| US-20150225372-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-13 | — | — | US | disclosed |
| US-9040540-B2 | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-05-26 | — | — | US | disclosed |
| US-9040540-B2 | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-05-26 | — | — | US | disclosed |
| US-20140315925-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| US-20140315925-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| WO-2013068755-A1 | 5-(PYRIDIN-2-YL-AMINO)-PYRAZINE-2-CARBONITRILE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304493-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CHEK1, CHEK2, PLK1 | CHEK1 1/4885CHEK2 2/4885KCNH2 3837/4885 |
| US-20150225372-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CHEK1, CHEK2, PLK1 | CHEK1 1/4885CHEK2 2/4885KCNH2 3837/4885 |
| US-20140315925-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CHEK1, CHEK2, PLK1 | CHEK1 1/4885CHEK2 2/4885KCNH2 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.